73863-45-3

Basic information

• Product Name: 4-chloro-N-(3-methoxyphenyl)butanamide
• Synonyms: 4-chloro-N-(3-methoxyphenyl)butanamide
• CAS NO: 73863-45-3
• Molecular Weight: 227.691
• Mol File: 73863-45-3.mol

Chemical Properties

• CAS DataBase Reference: 4-chloro-N-(3-methoxyphenyl)butanamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-chloro-N-(3-methoxyphenyl)butanamide(73863-45-3)
• EPA Substance Registry System: 4-chloro-N-(3-methoxyphenyl)butanamide(73863-45-3)

Safety Data

• Hazardous Substances Data: 73863-45-3(Hazardous Substances Data)

Upstream product

• 536-90-3 m-Anisidine 
• 4635-59-0 4-Chlorobutanoyl chloride 

Downstream Products

• 1444513-64-7 diethyl [N-(3-methoxyphenyl)carbamoyl]propylphosphonate 
• 1444514-61-7 sodium hydrogen [N-(3-methoxyphenyl)carbamoyl]propylphosphonate 
• 1444514-12-8 [N-(3-methoxyphenyl)carbamoyl]propylphosphonic acid 
• 73863-51-1 2-chloro-3-(2-chloro-ethyl)-7-methoxy-quinoline 

Relevant articles and documents

One-Pot Tandem Assembly of Amides, Amines, and Ketones: Synthesis of C4-Quaternary 3,4- And 1,4-Dihydroquinazolines

A multicomponent tandem assembly procedure for the synthesis of diverse C4-quaternary 3,4-dihydroquinazolines from amides, amines, and ketones has been developed. The one-pot reaction involves successive triflic anhydride mediated amide dehydration, ketimine addition, and Pictet-Spengler-like cyclization processes and affords products in up to 92% yield. Conversion of 3,4-dihydroquinazolines to the corresponding 1,4-dihydroquinazolines via a two-step N1 dealkylation and regioselective N3 functionalization protocol, including computational rationale for the observed regioselectivity, is also described.

Exploring DOXP-reductoisomerase binding limits using phosphonated N-aryl and N-heteroarylcarboxamides as DXR inhibitors

DOXP-reductoisomerase (DXR) is a validated target for the development of antimalarial drugs to address the increase in resistant strains of Plasmodium falciparum. Series of aryl- and heteroarylcarbamoylphosphonic acids, their diethyl esters and disodium salts have been prepared as analogues of the potent DXR inhibitor fosmidomycin. The effects of the carboxamide N-substituents and the length of the methylene linker have been explored using in silico docking studies, saturation transfer difference NMR spectroscopy and enzyme inhibition assays using both EcDXR and PfDXR. These studies indicate an optimal linker length of two methylene units and have confirmed the importance of an additional binding pocket in the PfDXR active site. Insights into the constraints of the PfDXR binding site provide additional scope for the rational design of DXR inhibitors with increased ligand-receptor interactions.